|
|
|
|
| LEADER |
02820nam a22004815i 4500 |
| 001 |
978-3-319-39664-4 |
| 003 |
DE-He213 |
| 005 |
20160514125326.0 |
| 007 |
cr nn 008mamaa |
| 008 |
160514s2016 gw | s |||| 0|eng d |
| 020 |
|
|
|a 9783319396644
|9 978-3-319-39664-4
|
| 024 |
7 |
|
|a 10.1007/978-3-319-39664-4
|2 doi
|
| 040 |
|
|
|d GrThAP
|
| 050 |
|
4 |
|a QR180-189.5
|
| 072 |
|
7 |
|a MJCM
|2 bicssc
|
| 072 |
|
7 |
|a MED044000
|2 bisacsh
|
| 082 |
0 |
4 |
|a 616.079
|2 23
|
| 100 |
1 |
|
|a Jankowski, Marek.
|e author.
|
| 245 |
1 |
0 |
|a Interleukin-27: Biological Properties and Clinical Application
|h [electronic resource] /
|c by Marek Jankowski, Tomasz Wandtke.
|
| 264 |
|
1 |
|a Cham :
|b Springer International Publishing :
|b Imprint: Springer,
|c 2016.
|
| 300 |
|
|
|a VI, 86 p. 5 illus. in color.
|b online resource.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 347 |
|
|
|a text file
|b PDF
|2 rda
|
| 490 |
1 |
|
|a SpringerBriefs in Immunology,
|x 2194-2773
|
| 505 |
0 |
|
|a IL-27: Structure, Regulation and Variability -- IL-27: A Key Player in Immune Regulation -- IL-27 in Health and Disease.
|
| 520 |
|
|
|a This volume focuses on various aspects of interleukin-27 (IL-27), especially its potential for clinical applications. The authors discuss the downstream signaling from the IL-27 receptor and its molecular targets in immune cells including Th1, Th2, Th17, Treg, Tr1, Tfh, B cells, DCs and macrophages. The inhibition of Th17 cells by IL-27 is vital for the maintenance of the feto-maternal tolerance and the prevention of lupus, multiple sclerosis, autoimmune uveitis, immune thrombocytopenia and atherosclerosis. However, the same inhibitory capabilities compromise the immune response to bacterial pathogens, and IL-27 is a pathogenic factor in sepsis and tuberculosis. Also covered are the conflicting reports on the role of IL-27 in rheumatoid arthritis, the effect of IL-27 on epithelia, which seems to play a role in asthma, psoriasis and inflammatory bowel diseases, and the direct cytotoxic and anti-vascular effects of IL-27, which make it a promising agent for the treatment of cancer. Accordingly, this volume will be of interest to researchers and clinicians alike.
|
| 650 |
|
0 |
|a Medicine.
|
| 650 |
|
0 |
|a Immunology.
|
| 650 |
|
0 |
|a Cytokines.
|
| 650 |
|
0 |
|a Growth factors.
|
| 650 |
1 |
4 |
|a Biomedicine.
|
| 650 |
2 |
4 |
|a Immunology.
|
| 650 |
2 |
4 |
|a Cytokines and Growth Factors.
|
| 700 |
1 |
|
|a Wandtke, Tomasz.
|e author.
|
| 710 |
2 |
|
|a SpringerLink (Online service)
|
| 773 |
0 |
|
|t Springer eBooks
|
| 776 |
0 |
8 |
|i Printed edition:
|z 9783319396620
|
| 830 |
|
0 |
|a SpringerBriefs in Immunology,
|x 2194-2773
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1007/978-3-319-39664-4
|z Full Text via HEAL-Link
|
| 912 |
|
|
|a ZDB-2-SBL
|
| 950 |
|
|
|a Biomedical and Life Sciences (Springer-11642)
|
